DENVER, CO—Longer-term follow-up data from the ABSORB II and III trials confirm the significantly increased risk of thrombotic events with the Absorb bioresorbable vascular scaffold (BVS; Abbott ...
WASHINGTON, DC—Three-year outcomes from the ABSORB II trial, a time point in which the Absorb GT1 bioresorbable vascular scaffold should be degraded, did not result in an improvement in vasomotor tone ...
Absorb, Abbott's coronary stent system made to fully dissolve in the patient's body, has finally been approved by FDA. The agency's nod comes as the device is already available in more than 100 ...
Abbott said it will monitor bioabsorbable stent implantations in Europe, following a high rate of heart attacks in European Absorb GT1 patients, plus a separate FDA safety alert regarding adverse ...
CALGARY, Alberta--(BUSINESS WIRE)--Absorb Software Inc., a leading provider of cloud-based learning and performance management software for corporations and higher education institutions, announced ...
WCAS has completed its acquisition of Absorb Software, a provider of cloud-based learning and performance management software. Mike Owens will remain CEO, while former WCAS operating partner Tim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results